CoChat

Levothyroxine/Liothyronine Combination Therapy and Quality of Life: Is It All about Weight Loss?

Open access
Michaelsson, Luba Freja, la Cour, Jeppe Lerche, Medici, Bjarke Borregaard, Watt, Torquil, Faber, Jens, Nygaard, Birte · 2018 · European Thyroid Journal

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Objectives: According to one hypothesis, the popularity of levothyroxine (L-T 4)/liothyronine (L-T 3) combination therapy relates to weight loss. The purpose of this study was to detect a possible correlation between thyroid-related quality of life (QoL) and weight loss in hypothyroid patients switched from L-T 4 monotherapy to L-T 4/L-T 3 combination therapy. Methods: In an open-label cohort study, all hypothyroid patients referred to the University Hospital endocrine clinic due to persistent symptoms despite adequate L-T 4 monotherapy (without other explanations for the symptoms) were switched from L-T 4 monotherapy to L-T 4/ L-T 3 combination therapy at a ratio of approximately 17/1. At baseline and after 3 months of treatment we measured: QoL by the Thyroid Patient-Reported Outcome (ThyPRO-39) questionnaire, thyroid hormones, body weight, body composition by a DEXA-scan, and cognitive function by evaluating participants’ reaction time as well as working memory by the California Computerized Assessment Package (CalCAP®). QoL was re-evaluated after 12 months. Results: Twenty-three patients participated (91% women, median age 47 years). The ThyPRO-39 composite score decreased from a median of 54 (quartiles: 34, 74) to 15 (11, 28) after 3 months (p < 0.0001), and 20 (14, 26) after 12 months, indicating a better QoL. There was no change in body weight, and no correlations between QoL and weight. There was a slight improvement in cognitive function, whereas body composition, heart rate, and serum TSH did not change. Conclusion: Our study on hypothyroid patients switched from L-T 4 monotherapy to L-T 4/L-T 3 combination therapy showed a substantial improvement in QoL measured by the ThyPRO-39. This improvement could not be explained by weight loss.

Overview

Integrity signals

Registry

Crossref · 10.1159/000490383

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 18 references

Cited by

See all 30

Metadata

Authors
Michaelsson, L. F., la Cour, J. L., Medici, B. B., Watt, T., Faber, J., & Nygaard, B.
Affiliations
  • University of Copenhagen (DK)
  • 1Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
Venue
European Thyroid Journal
Published
2018-07-13
Volume
7
Issue
5
Pages
243-250
ISSN
  • 2235-0640 (ISSN-L)
  • 2235-0802
OpenAlex
W2883142002
Cited by
30
References
18
Citations by year
2026: 1 · 2025: 5 · 2024: 4 · 2023: 1 · 2022: 6 · 2021: 5 · 2020: 4 · 2019: 4
FWCI
2.59
Type
journal article
Language
en
Open access
Locations
  • European Thyroid Journal (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
levothyroxine, liothyronine, combination thyroid hormone therapy, hypothyroidism, quality of life, weight loss, cognitive function, body composition, thyroid-stimulating hormone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Levothyroxine/Liothyronine Combination Therapy and Quality of Life: Is It All about Weight Loss? https://app.cochat.ai/papers/10.1159/000490383
The paper
Michaelsson, L. F., la Cour, J. L., Medici, B. B., Watt, T., Faber, J., & Nygaard, B. (2018). Levothyroxine/Liothyronine Combination Therapy and Quality of Life: Is It All about Weight Loss? European Thyroid Journal. https://doi.org/10.1159/000490383

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.